Abstract
MicroRNAs are important epigenetic regulators of protein expression by triggering degradation of target mRNAs and/or inhibiting their translation. Dysregulation of microRNA expression has been reported in several cancers, including prostate cancer (PC). We comprehensively characterized the proteomic footprint of a panel of 12 microRNAs that are potently suppressed in metastatic PC (SiM-miRNAs: miR-1, miR-133a, miR-133b, miR-135a, miR-143-3p, miR-145-3p, miR-205, miR-221-3p, miR-221-5p, miR-222-3p, miR-24-1-5p, and miR-31) using reverse-phase proteomic arrays. Re-expression of these SiM-miRNAs in PC cells suppressed cell proliferation and targeted key oncogenic pathways, including cell cycle, apoptosis, Akt/mammalian target of rapamycin signaling, metastasis and the androgen receptor (AR) axis. However, only 12%, at most, of these observed protein expression changes could be explained by predicted direct binding of miRNAs to corresponding mRNAs, suggesting that the majority of these proteomic effects result indirectly. AR and its steroid receptor coactivators (SRCs; SRC-1, -2 and -3) were recurrently affected by these SiM-miRNAs. In agreement, we identified inverse correlations between expression of these SiM-miRNAs and early clinical recurrence, as well as with AR transcriptional activity in human PC tissues. We also identified robust induction of miR-135a by androgen and strong direct binding of AR to the miR-135a locus. As miR-135a potently suppresses AR expression, this results in a negative feedback loop that suppresses AR protein expression in an androgen-dependent manner, while de-repressing AR expression upon androgen deprivation. Our results demonstrate that epigenetic silencing of these SiM-miRNAs can result in increased AR axis activity and cell proliferation, thus contributing to disease progression. We further demonstrate that a negative feedback loop involving miR-135a can restore AR expression under androgen-deprivation conditions, thus contributing to the upregulation of AR protein expression in castration-resistant PC. Finally, our unbiased proteomic profiling demonstrates that the majority of actual protein expression changes induced by SiM-miRNAs cannot be explained based on predicted direct interactions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nelson PS . Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 2012; 30: 644–646.
Mitsiades N . A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res 2013; 73: 4599–4605.
Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ . Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002; 62: 1008–1013.
Debes JD, Tindall DJ . Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488–1490.
Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315–4319.
Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T . Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61: 3550–3555.
Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69: 8141–8149.
Gregory CW, Johnson RT Jr., Mohler JL, French FS, Wilson EM . Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892–2898.
Agoulnik IU, Vaid A, Bingman WE 3rd, Erdeme H, Frolov A, Smith CL et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005; 65: 7959–7967.
Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE 3rd, Erdem H et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006; 66: 10594–10602.
Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ . Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res 2006; 66: 11039–11046.
Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res 2008; 68: 5460–5468.
Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005; 65: 7976–7983.
Tien JC, Liu Z, Liao L, Wang F, Xu Y, Wu YL et al. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. Cancer Res 2013; 73: 3997–4008.
Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 2012; 72: 6142–6152.
Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314–319.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer cell 2010; 18: 11–22.
Vidigal JA, Ventura A . The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol 2014; 25: 137–147.
Liu C, Tang DG . MicroRNA regulation of cancer stem cells. Cancer Res 2011; 71: 5950–5954.
Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, Tang DG . Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res 2012; 72: 3393–3404.
Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 2013; 73: 1232–1244.
Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T . MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130–6135.
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68: 6162–6170.
Fang YX, Gao WQ . Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 2014; 33: 135–147.
Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 2012; 40: 3689–3703.
Hart M, Nolte E, Wach S, Szczyrba J, Taubert H, Rau TT et al. Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. Mol Cancer Res 2014; 12: 250–263.
Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I et al. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res 2012; 72: 3618–3630.
Formosa A, Lena AM, Markert EK, Cortelli S, Miano R, Mauriello A et al. DNA methylation silences miR-132 in prostate cancer. Oncogene 2013; 32: 127–134.
Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 2014; 33: 5173–5182.
Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C et al. Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene 2013; 32: 2891–2899.
Ozen M, Creighton CJ, Ozdemir M, Ittmann M . Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27: 1788–1793.
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009; 69: 7165–7169.
Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y et al. MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene 2013; 32: 4139–4147.
Yue D, Liu H, Huang Y . Survey of computational algorithms for microRNA target prediction. Curr Genomics 2009; 10: 478–492.
Witkos TM, Koscianska E, Krzyzosiak WJ . Practical aspects of microRNA target prediction. Curr Mol Med 2011; 11: 93–109.
Reyes-Herrera PH, Ficarra E . One decade of development and evolution of microRNA target prediction algorithms. Genomics Proteomics Bioinformatics 2012; 10: 254–263.
Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masia E, Casanova J et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol 2014; 192: 252–259.
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239–243.
Erhard F, Haas J, Lieber D, Malterer G, Jaskiewicz L, Zavolan M et al. Widespread context dependency of microRNA-mediated regulation. Genome Res 2014; 24: 906–919.
Haecker I, Gay LA, Yang Y, Hu J, Morse AM, McIntyre LM et al. Ago HITS-CLIP expands understanding of Kaposi's sarcoma-associated herpesvirus miRNA function in primary effusion lymphomas. PLoS Pathog 2012; 8: e1002884.
Kishore S, Jaskiewicz L, Burger L, Hausser J, Khorshid M, Zavolan M . A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. Nat Methods 2011; 8: 559–564.
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013; 495: 333–338.
Gottwein E, Corcoran DL, Mukherjee N, Skalsky RL, Hafner M, Nusbaum JD et al. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe 2011; 10: 515–526.
Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog 2012; 8: e1002484.
Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A et al. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene 2014; 34: 2846–2855.
He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM et al. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci USA 2014; 111: 18261–18266.
Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res 2014; 74: 5631–5643.
Taipaleenmaki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL et al. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res 2015; 75: 1433–1444.
Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011; 474: 390–394.
Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011; 473: 43–49.
Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009; 16: 206–216.
Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P . The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009; 69: 3356–3363.
Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M et al. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 2014; 33: 2790–2800.
Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL et al. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate 2012; 72: 1093–1103.
Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009; 69: 2287–2295.
Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009; 48: 366–380.
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011; 20: 457–471.
Ostling P, Leivonen SK, Aakula A, Kohonen P, Makela R, Hagman Z et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 2011; 71: 1956–1967.
Therneau TM, Grambsch PM . Modeling Survival Data: Extending the Cox Model. Springer:, New York, USA, 2000.
Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 2013; 5: 169ra10.
Acknowledgements
We acknowledge the joint participation by Adrienne Helis Malvin Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine. This work was also supported by the American Cancer Society RSG-14-218-01-TBG (to NM), the Prostate Cancer Foundation (to BWO and NM), the Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator and Career Development Awards (both to NM), NICHD 8818 and Department of Defense Breast Cancer Research Program Innovator Award (to BWO), the Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center (P30-DK079638) at Baylor College of Medicine (to NM), and an Alkek Foundation for Molecular Discovery Pilot grant (to CC). NM is a Dan L. Duncan Scholar, a Caroline Wiess Law Scholar and a member of the Dan L. Duncan Cancer Center (supported by the NCI Cancer Center Support grant P30CA125123) and the Center for Drug Discovery at Baylor College of Medicine. We thank the assistance of the Shared Resources of the Dan L. Duncan Cancer Center (supported by the NCI Cancer Center Support grant P30CA125123) and the Functional Proteomics RPPA Core Facility (The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Coarfa, C., Fiskus, W., Eedunuri, V. et al. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene 35, 2345–2356 (2016). https://doi.org/10.1038/onc.2015.295
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2015.295
This article is cited by
-
Preliminary study on miRNA in prostate cancer
World Journal of Surgical Oncology (2023)
-
Targeting androgen receptor signaling with MicroRNAs and Curcumin: a promising therapeutic approach for Prostate Cancer Prevention and intervention
Cancer Cell International (2021)
-
miRNAs expression signature potentially associated with lymphatic dissemination in locally advanced prostate cancer
BMC Medical Genomics (2020)
-
miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo
BMC Cancer (2019)
-
miR-221-5p enhances cell proliferation and metastasis through post-transcriptional regulation of SOCS1 in human prostate cancer
BMC Urology (2018)